ClinicalTrials.gg
TerminatedNCT06042920Updated Apr 17, 2026Results posted

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

A Phase 4 interventional study of Deucravacitinib and Placebo in Palmoplantar Psoriasis and Genital Psoriasis, sponsored by Bristol-Myers Squibb. Terminated at 31 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Why this study was terminated
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.

Enrollment
13th of 26
130 · median 102
Started
2023
with 3 others
Phase 4
8 of 26
2 open now
Registered
18th of 26
by date
Lead sponsor
18 of 26
Bristol-Myers Squibb

Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 13th largest by enrollment, is one of 4 that started in 2023, is one of 8 in phase 4, and was the 18th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About deucravacitinib

deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing deucravacitinib in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.

03

Conditions studied

  • Palmoplantar Psoriasis
  • Genital Psoriasis

Browse trials for

Keywords

  • Deucravacitinib
  • BMS-986165
  • SOTYKTU
  • Plaque psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Inclusion Criteria for Non-Pustular Palmoplantar Psoriasis

  • Men and women diagnosed with stable plaque psoriasis with involvement of the palm(s)and/or sole(s) for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
  • Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1.
  • Moderate-to-severe non-pustular PP psoriasis, defined as pp-PGA score of ≥ 3 on a 5-pointscale and pp-PASI ≥ 8 at both screening visit and Day 1.

    • A total maximum of 5 sterile pustules across both palms and soles limited only to psoriatic plaques will be allowed.
  • Evidence of typical plaque psoriasis outside palms and soles at both screening visit and Day 1.
  • Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
  • Failed to respond to, or intolerant of ≥ 1 topical therapy.

Inclusion Criteria for Genital Psoriasis

  • Men and women diagnosed with stable plaque psoriasis with involvement of the genital area for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
  • Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1.
  • Moderate-to-severe GenPs, defined as static Physician's Global Assessment of Genitalia (s-PGA-G) score of ≥ 3 on a 6-point scale at both screening visit and Day 1.
  • Evidence of typical plaque psoriasis in a non-genital area at both screening visit and Day 1.
  • Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
  • Failed to respond to, or intolerant of ≥ 1 topical therapy.

Key Exclusion Criteria:

Target Disease Exceptions

  • Has non-plaque psoriasis (for PP pustulosis, PP pustular psoriasis, isolated pustules on palms or soles with or without erythema outside psoriatic plaques, guttate, pustular, erythrodermic, and drug-induced psoriasis) at screening or Day 1.

Other protocol-defined inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Deucravacitinib

    Drug: Deucravacitinib

  • Placebo comparator
    Placebo followed by Deucravacitinib

    Drug: Deucravacitinib · Drug: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986165, SOTYKTU

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response

    PASI-75 is defined as the percentage of participants who achieve at least a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI) total score. PASI assesses erythema, thickness, and scaling of psoriatic lesions (each rated 0-4), weighted by body region involvement (head, arms, trunk, legs), producing a total score from 0-72, where higher scores indicate more severe disease. Baseline is the Week 0 assessment. PASI-75 responder defined as a 75% improvement from baseline in the PASI score.

    Time frame: Week 16

  2. Percentage of Participants Achieving Static Physician's Global Assessment of Genitalia (sPGA-G) Response

    The Static Physician's Global Assessment (sPGA) OF Genitalia is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The sPGA-G 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieve a Palmoplantar Physician Global Assessment (Pp-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16

    The Palmoplantar Physician's Global Assessment (pp-PGA) is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The pp-PGA 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.

    Time frame: Week 16

  2. Change From Baseline in Genital Psoriasis Itch (GenPs) Numeric Rating Scale (NRS) Score at Week 16

    The Genital Psoriasis Symptoms Scale (GPSS) is a participant-administered questionnaire that contains 8 items regarding GenPs symptoms and has a recall period of 24 hours. The items separately address itch, pain, discomfort, stinging, burning, redness, scaling, and cracking on an 11-point scale where 0 represents "no symptom" and 10 represents "worst symptom imaginable". A total score ranging from 0 (no GenPs symptoms) to 80 (worst imaginable GenPs symptoms)

    Time frame: Week 16

  3. Number of Participants With Adverse Events

    Adverse Events (AEs) are any new or worsening medical occurrences in participants receiving study treatment, regardless of whether they are related to the treatment. AEs include any unfavorable and unintended sign, symptom, or disease temporally associated with treatment. Serious Adverse Events (SAEs) are defined as events that result in death, are life-threatening, require or prolong hospitalization, cause persistent or significant disability, are congenital anomalies/birth defects, or are otherwise medically significant.

    Time frame: Week 0 through Week 16

  4. Number of Participants With Worst Toxicity Grade 3 or Grade 4 Laboratory Test Results

    Blood samples were collected to assess the laboratory parameters. Laboratory toxicities are graded using NCI CTCAE v3.0. Grade 3 and 4 represent severe and life-threatening abnormalities, respectively.

    Time frame: Week 0 through Week 16

  5. Number of Participants With Vital Sign Summaries Per Categories

    Vital signs assessment included heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Heart rate was measured in beats/min and DBP and SBP was measured in mmHG.

    Time frame: Week 0 through Week 16

07

Results

Posted Apr 17, 2026

Participant flow

Placebo-Controlled Period
Participant flow — Placebo-Controlled Period
MilestonePlacebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Palmoplantar Psoriasis - PlaceboPlacebo-Controlled Genital Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Genital Psoriasis - PlaceboActive Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mgActive Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mgActive Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mgActive Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg
Started301556290000
Completed13829110000
Not completed17727180000
Withdrew: Lost to follow-up00020000
Withdrew: Site terminated by sponsor00100000
Withdrew: Withdrawal by subject22120000
Withdrew: Study terminated by sponsor15525130000
Withdrew: Lack of efficacy00010000
Active Treatment Period
Participant flow — Active Treatment Period
MilestonePlacebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Palmoplantar Psoriasis - PlaceboPlacebo-Controlled Genital Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Genital Psoriasis - PlaceboActive Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mgActive Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mgActive Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mgActive Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg
Started00001382911
Completed00003152
Not completed0000107249
Withdrew: Site terminated by sponsor00000001
Withdrew: Other reasons00000001
Withdrew: Withdrawal by subject00000120
Withdrew: Lost to follow-up00001010
Withdrew: Adverse event00001000
Withdrew: Not reported00002022
Withdrew: Study terminated by sponsor000066195

Outcome measures

PrimaryPercentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response

PASI-75 is defined as the percentage of participants who achieve at least a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI) total score. PASI assesses erythema, thickness, and scaling of psoriatic lesions (each rated 0-4), weighted by body region involvement (head, arms, trunk, legs), producing a total score from 0-72, where higher scores indicate more severe disease. Baseline is the Week 0 assessment. PASI-75 responder defined as a 75% improvement from baseline in the PASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response
percentage of participantsPlacebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QDPlacebo Contolled - Palmoplantar Psoriasis - Placebo
Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response31.3 (11.0 to 58.7)33.3 (7.5 to 70.1)
PrimaryPercentage of Participants Achieving Static Physician's Global Assessment of Genitalia (sPGA-G) Response

The Static Physician's Global Assessment (sPGA) OF Genitalia is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The sPGA-G 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician's Global Assessment of Genitalia (sPGA-G) Response
percentage of participantsPlacebo-Controlled Genital Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Genital Psoriasis - Placebo
Percentage of Participants Achieving Static Physician's Global Assessment of Genitalia (sPGA-G) Response48.4 (30.2 to 66.9)0 (0 to 24.7)
SecondaryPercentage of Participants Who Achieve a Palmoplantar Physician Global Assessment (Pp-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16

The Palmoplantar Physician's Global Assessment (pp-PGA) is a 5-point scale evaluating psoriasis severity based on erythema, scale, and induration. Scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe; higher scores indicate worse disease. The pp-PGA 0/1 response is defined as the percentage of participants achieving a score of 0 or 1 with at least a 2-point improvement from baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Palmoplantar Physician Global Assessment (Pp-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16
percentage of participantsPlacebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Palmoplantar Psoriasis - Placebo
Percentage of Participants Who Achieve a Palmoplantar Physician Global Assessment (Pp-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 1618.8 (4.0 to 45.6)11.1 (0.3 to 48.2)
SecondaryChange From Baseline in Genital Psoriasis Itch (GenPs) Numeric Rating Scale (NRS) Score at Week 16

The Genital Psoriasis Symptoms Scale (GPSS) is a participant-administered questionnaire that contains 8 items regarding GenPs symptoms and has a recall period of 24 hours. The items separately address itch, pain, discomfort, stinging, burning, redness, scaling, and cracking on an 11-point scale where 0 represents "no symptom" and 10 represents "worst symptom imaginable". A total score ranging from 0 (no GenPs symptoms) to 80 (worst imaginable GenPs symptoms)

Time frame:
Week 16
Reported as:
Mean · score on a scale
Change From Baseline in Genital Psoriasis Itch (GenPs) Numeric Rating Scale (NRS) Score at Week 16
score on a scalePlacebo-Controlled Genital Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Genital Psoriasis - Placebo
Change From Baseline in Genital Psoriasis Itch (GenPs) Numeric Rating Scale (NRS) Score at Week 16-1.9 ± 3.23-0.8 ± 2.95
SecondaryNumber of Participants With Adverse Events

Adverse Events (AEs) are any new or worsening medical occurrences in participants receiving study treatment, regardless of whether they are related to the treatment. AEs include any unfavorable and unintended sign, symptom, or disease temporally associated with treatment. Serious Adverse Events (SAEs) are defined as events that result in death, are life-threatening, require or prolong hospitalization, cause persistent or significant disability, are congenital anomalies/birth defects, or are otherwise medically significant.

Time frame:
Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPlacebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Palmoplantar Psoriasis - PlaceboPlacebo-Controlled Genital Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Genital Psoriasis - Placebo
Adverse Events1773115
Serious Adverse Events0010
SecondaryNumber of Participants With Worst Toxicity Grade 3 or Grade 4 Laboratory Test Results

Blood samples were collected to assess the laboratory parameters. Laboratory toxicities are graded using NCI CTCAE v3.0. Grade 3 and 4 represent severe and life-threatening abnormalities, respectively.

Time frame:
Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grade 3 or Grade 4 Laboratory Test Results
ParticipantsPlacebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Palmoplantar Psoriasis - PlaceboPlacebo-Controlled Genital Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Genital Psoriasis - Placebo
Number of Participants With Worst Toxicity Grade 3 or Grade 4 Laboratory Test Results0020
SecondaryNumber of Participants With Vital Sign Summaries Per Categories

Vital signs assessment included heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Heart rate was measured in beats/min and DBP and SBP was measured in mmHG.

Time frame:
Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Summaries Per Categories
ParticipantsPlacebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Palmoplantar Psoriasis - PlaceboPlacebo-Controlled Genital Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Genital Psoriasis - Placebo
HR VALUE > 100 AND CHANGE FROM BASELINE > 300000
HR VALUE < 55 AND CHANGE FROM BASELINE < -150000
SBP VALUE > 140 AND CHANGE FROM BASELINE > 201030
SBP VALUE < 90 AND CHANGE FROM BASELINE < -200000
DBP VALUE > 90 AND CHANGE FROM BASELINE > 103162
DBP VALUE < 55 AND CHANGE FROM BASELINE < -100010

Adverse events

Collected over All-cause mortality, serious and non-serious adverse events were collected from Week 0 through Week 52.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QD0/30 (0%)0/30 (0%)9/30 (30%)
Placebo-Controlled Palmoplantar Psoriasis - Placebo0/15 (0%)0/15 (0%)7/15 (46.7%)
Placebo-Controlled Genital Psoriasis - BMS-986165 6mg QD0/56 (0%)1/56 (1.8%)10/56 (17.9%)
Placebo-Controlled Genital Psoriasis - Placebo0/29 (0%)0/29 (0%)10/29 (34.5%)
Active Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg0/13 (0%)1/13 (7.7%)2/13 (15.4%)
Active Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mg0/8 (0%)2/8 (25%)1/8 (12.5%)
Active Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mg0/29 (0%)4/29 (13.8%)7/29 (24.1%)
Active Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg0/10 (0%)0/10 (0%)2/10 (20%)
Most frequent serious events
Most frequent serious events
EventPlacebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Palmoplantar Psoriasis - PlaceboPlacebo-Controlled Genital Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Genital Psoriasis - PlaceboActive Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mgActive Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mgActive Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mgActive Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg
Hip fractureInjury, poisoning and procedural complications0/300/150/560/290/131/80/290/10
Knee arthroplastySurgical and medical procedures0/300/150/560/290/131/80/290/10
Small cell lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/300/150/560/291/130/80/290/10
Coronary artery occlusionCardiac disorders0/300/150/560/290/130/81/290/10
Haemorrhoidal haemorrhageGastrointestinal disorders0/300/150/560/290/130/81/290/10
CellulitisInfections and infestations0/300/150/560/290/130/81/290/10
PneumoniaInfections and infestations0/300/150/560/290/130/81/290/10
Cardiac failure congestiveCardiac disorders0/300/151/560/290/130/80/290/10
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlacebo-Controlled Palmoplantar Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Palmoplantar Psoriasis - PlaceboPlacebo-Controlled Genital Psoriasis - BMS-986165 6mg QDPlacebo-Controlled Genital Psoriasis - PlaceboActive Treatment Palmoplantar Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mgActive Treatment Palmoplantar Psoriasis - Placebo - Deucravacitinib 6mgActive Treatment Genital Psoriasis - Deucravacitinib 6mg - Deucravacitinib 6mgActive Treatment Genital Psoriasis - Placebo - Deucravacitinib 6mg
NasopharyngitisInfections and infestations2/300/152/564/290/130/82/290/10
PneumoniaInfections and infestations0/300/150/560/291/131/81/290/10
Pharyngitis streptococcalInfections and infestations0/300/151/560/291/130/80/291/10
Tinea crurisInfections and infestations0/300/150/560/290/130/80/291/10
Liver function test increasedInvestigations0/300/150/560/290/130/80/291/10
CholecystitisHepatobiliary disorders0/300/150/560/291/130/80/290/10
InfluenzaInfections and infestations2/301/150/561/291/130/81/290/10
EczemaSkin and subcutaneous tissue disorders0/300/150/560/291/130/80/290/10
PyrexiaGeneral disorders0/300/150/562/290/130/80/290/10
COVID-19Infections and infestations0/300/150/562/290/130/80/290/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo Contolled - Palmoplantar Psoriasis - BMS-986165 6 mg QDPlacebo Contolled - Palmoplantar Psoriasis - PlaceboPlacebo Contolled - Genital Psoriasis - BMS-986165 6mg QDPlacebo Contolled - Genital Psoriasis - PlaceboTotal
<=18 years00000
Between 18 and 65 years21105224107
>=65 years954523
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Contolled - Palmoplantar Psoriasis - BMS-986165 6 mg QDPlacebo Contolled - Palmoplantar Psoriasis - PlaceboPlacebo Contolled - Genital Psoriasis - BMS-986165 6mg QDPlacebo Contolled - Genital Psoriasis - PlaceboTotal
Female17617949
Male139392081
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Contolled - Palmoplantar Psoriasis - BMS-986165 6 mg QDPlacebo Contolled - Palmoplantar Psoriasis - PlaceboPlacebo Contolled - Genital Psoriasis - BMS-986165 6mg QDPlacebo Contolled - Genital Psoriasis - PlaceboTotal
AMERICAN INDIAN OR ALASKA NATIVE00101
ASIAN31116
BLACK OR AFRICAN AMERICAN01315
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER00000
WHITE27134926115
UNKNOWN00202
NOT REPORTED00011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Contolled - Palmoplantar Psoriasis - BMS-986165 6 mg QDPlacebo Contolled - Palmoplantar Psoriasis - PlaceboPlacebo Contolled - Genital Psoriasis - BMS-986165 6mg QDPlacebo Contolled - Genital Psoriasis - PlaceboTotal
HISPANIC OR LATINO93261351
NOT HISPANIC OR LATINO2112291678
UNKNOWN00000
NOT REPORTED00101
08

Study locations

31 sites
  • Local Institution - 0050
    Phoenix, Arizona 85006-2722, United States
  • Local Institution - 0015
    Fountain Valley, California 92708, United States
  • Local Institution - 0009
    Los Angeles, California 90045-3606, United States
  • Local Institution - 0004
    Santa Monica, California 90404, United States
  • Local Institution - 0057
    Skokie, Illinois 60077-1049, United States
  • Local Institution - 0052
    Indianapolis, Indiana 46250, United States
  • Local Institution - 0053
    Plainfield, Indiana 46168-2792, United States
  • Local Institution - 0029
    Rockville, Maryland 20850-6243, United States
  • Local Institution - 0012
    Detroit, Michigan 48202-3141, United States
  • Local Institution - 0005
    East Windsor, New Jersey 08520-2505, United States
  • Local Institution - 0002
    New York, New York 10003, United States
  • Local Institution - 0008
    New York, New York 10075, United States
  • Local Institution - 0062
    New York, New York 10128, United States
  • Local Institution - 0001
    Winston-Salem, North Carolina 27157, United States
  • Local Institution - 0066
    Boardman, Ohio 44512, United States
  • Local Institution - 0055
    Mayfield Heights, Ohio 44124-4005, United States
  • Local Institution - 0056
    Pittsburgh, Pennsylvania 15213-3403, United States
  • Local Institution - 0010
    Houston, Texas 77004, United States
  • Local Institution - 0007
    Norfolk, Virginia 23502-3933, United States
  • Local Institution - 0033
    Mill Creek, Washington 98012-1797, United States
  • Local Institution - 0043
    Ciudad Autónoma Buenos Aires, B 1425, Argentina
  • Local Institution - 0037
    Ciudad Autónoma Buenos Aires, B C1428DZF, Argentina
  • Local Institution - 0034
    Ciudad Autonoma Buenos Aires, C C1425DKG, Argentina
  • Local Institution - 0042
    Rosario, S 2000, Argentina
  • Local Institution - 0058
    Newmarket, Ontario L3Y 5G8, Canada
  • Local Institution - 0060
    Toronto, Ontario M3B 0A7, Canada
  • Local Institution - 0065
    Montreal, Quebec H1Y 3L1, Canada
  • Local Institution - 0054
    Montreal, Quebec H2X 2V1, Canada
  • Local Institution - 0059
    Québec, Quebec G1W 4R4, Canada
  • Local Institution - 0061
    Saint-Jérôme, Quebec J7Z 7E2, Canada
  • Local Institution - 0064
    Saskatoon, Saskatchewan S7K 2C1, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol-Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.htm

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Apr 2025, 18 months.

Results were first posted in Apr 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 21, 2023
StartActual
Oct 9, 2023
Primary completionActual
Apr 25, 2025
CompletionActual
Apr 25, 2025
Results first posted
Apr 17, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06042920
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Oct 9, 2023
Primary completion
Apr 25, 2025
Completion
Apr 25, 2025
Results posted
Apr 17, 2026
Last update
Apr 17, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion